JFS Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

JFS Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3	Closed	-$65	–	1945
2025 Q4	$65	Sell	3 -37	-93%	-$780	﹤0.01%	1896
2025 Q3	$771	Buy	+40	New	+$713	﹤0.01%	1678
2024 Q4	–	Sell	-11	Closed	-$1.37K	–	1990
2024 Q3	$1.37K	Hold	11	–	–	﹤0.01%	1613
2024 Q2	$1.74K	Buy	+11	New	+$1.41K	﹤0.01%	1493
2024 Q1	–	Sell	-2	Closed	-$193	–	2033
2023 Q4	$193	Sell	2 -1	-33%	-$96	﹤0.01%	1909
2023 Q3	$364	Hold	3	–	–	﹤0.01%	1788
2023 Q2	$344	Sell	3 -252	-99%	-$32.5K	﹤0.01%	1809
2023 Q1	$35.1K	Buy	255 +2	+0.8%	+$259	﹤0.01%	422
2022 Q4	$32.8K	Buy	253 +3	+1%	+$348	﹤0.01%	430
2022 Q3	$28K	Hold	250	–	–	﹤0.01%	497
2022 Q2	$19K	Buy	+250	New	+$18.4K	﹤0.01%	599
2015 Q2	–	Sell	-1,490	Closed	-$20K	–	524
2015 Q1	$20K	Hold	1,490	–	–	0.01%	285
2014 Q4	$22K	Buy	1,490 +60	+4%	+$1.02K	﹤0.01%	280
2014 Q3	$30K	Hold	1,430	–	–	0.01%	226
2014 Q2	$43K	Buy	+1,430	New	+$45.2K	0.01%	205

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JFS Wealth Advisors's SRPT Position: Q1 2026 in Review

JFS Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 3 shares — an estimated $65 sold.

JFS Wealth Advisors first reported a position in SRPT in Q2 2014 and held it in 15 quarters. The position peaked at $43K in Q2 2014. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

JFS Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
JFS Wealth Advisors sold 3 Sarepta Therapeutics shares in Q1 2026, an estimated $65.
JFS Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 15 quarters.
JFS Wealth Advisors's Sarepta Therapeutics position peaked at $43K in Q2 2014.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on JFS Wealth Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.